Fulgent Genetics (FLGT) Revenue (2015 - 2026)

Fulgent Genetics has disclosed Revenue across 12 years of filings, most recently posting $71.1 million for Q1 2026.

• Revenue for Q1 2026 came in at $71.1 million, down 3.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $237.4 million (down 18.82% YoY), and the FY2025 annual result was $322.7 million, up 13.83% from the prior year.
• Revenue came in at $71.1 million for Q1 2026 at Fulgent Genetics, up from $400000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $320.3 million in Q1 2022 to a low of $400000.0 in Q4 2025.
• The 5-year median for Revenue is $72.6 million (2024), against an average of $89.7 million.
• Peak annual rise in Revenue reached 17.18% in 2025, while the deepest fall reached 99.48% in 2025.
• Fulgent Genetics' Revenue stood at $105.7 million in 2022, then plunged by 33.27% to $70.5 million in 2023, then increased by 8.1% to $76.2 million in 2024, then plunged by 99.48% to $400000.0 in 2025, then soared by 17684.5% to $71.1 million in 2026.
• The last three Revenue figures came in at $71.1 million (Q1 2026), $400000.0 (Q4 2025), and $84.1 million (Q3 2025), per Business Quant data.